HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs
HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs The new technology behind HighField’s immu ...
HighField Biopharmaceuticals’ Clearance for Phase 2 Trial of HF1K16, a Unique Myeloid Cell Directed Immune Modulator, Follows Phase 1 Results to be Presented at AACR 2025 Meeting
HighField Biopharmaceuticals’ Clearance for Phase 2 Trial of HF1K16, a Unique Myeloid Cell Directed Immune Modulator, Follows Phase 1 Results to be Presented at AACR 2025 Meeting Topline data fr ...
Studies by HighField Biopharmaceuticals Show Advantages of Lipid Structure Design for Applying LNP Non-Viral Gene Therapies to Complex Diseases
Studies by HighField Biopharmaceuticals Show Advantages of Lipid Structure Design for Applying LNP Non-Viral Gene Therapies to Complex Diseases Research papers focused on the importance of LNP s ...
HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM T Cell Engager (HF50) To Treat Solid Tumor Cancers
HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM T Cell Engager (HF50) To Treat Solid Tumor Cancers A Phase 1 trial of HF50 to evaluate ...
Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers
Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers The data from the ongoi ...
HighField Biopharmaceuticals Files IND in China for Clinical Trial of HF50, a Unique Lipid-Based T Cell Engager, to Treat Solid Tumor Cancers
HighField Biopharmaceuticals Files IND in China for Clinical Trial of HF50, a Unique Lipid-Based T Cell Engager, to Treat Solid Tumor Cancers The company's groundbreaking immunoliposome, contain ...
HighField Biopharmaceuticals’ mRNA-based HFG1 Demonstrates Potential as a Longer Acting GLP-1R Agonist for Diabetic Control and Weight Loss
HighField Biopharmaceuticals’ mRNA-based HFG1 Demonstrates Potential as a Longer Acting GLP-1R Agonist for Diabetic Control and Weight Loss Preclinical results in naturally occurred diabetic mon ...
HighField Biopharmaceuticals ASCO 2024 Poster Presentation Shows HFK1, a Unique Immunoliposome May Improve Clinical Outcomes over Antibody Drug Conjugates
HighField Biopharmaceuticals ASCO 2024 Poster Presentation Shows HFK1, a Unique Immunoliposome May Improve Clinical Outcomes over Antibody Drug Conjugates HFK1 is the company’s groundbreaking dr ...
HighField Biopharmaceuticals to Present Preclinical Data of HFG1, a Unique mRNA-based GLP-1R Agonist, for Treatment of Diabetes, at ADA’s 84th Scientific Sessions
HighField Biopharmaceuticals to Present Preclinical Data of HFG1, a Unique mRNA-based GLP-1R Agonist, for Treatment of Diabetes, at ADA’s 84th Scientific Sessions Filing of a U.S. IND for HFG1 i ...
HighField Biopharmaceuticals Announces Two Abstracts Accepted for the 2024 ASCO Annual Meeting
HighField Biopharmaceuticals Announces Two Abstracts Accepted for the 2024 ASCO Annual Meeting The company is developing next generation lipid-based structures that kill cancer cells and expose ...
English 
简体中文